Literature DB >> 18990449

Biosynthesis and expression of VE-cadherin is regulated by the PI3K/mTOR signaling pathway.

Michael Bieri1, Melinda Oroszlan, Christian Zuppinger, Paul J Mohacsi.   

Abstract

Vascular endothelial (VE)-cadherin is an essential protein of adherens junctions of endothelial cells and plays a pivotal role in vascular homeostasis. Mammalian target of rapamycin complex 2 (mTORC2) deficient mice display defects in fetal vascular development. Blocking mTOR or the upstream kinase phosphoinositide 3-kinase (PI3K) led to a dose-dependently decrease of the VE-cadherin mRNA and protein expression. Immunofluorescent staining showed a strongly decreased expression of VE-cadherin at the interface of human umbilical endothelial cells (HUVECs) followed by intercellular gap formation. Herewith, we demonstrated that the expression of VE-cadherin is dependent on mTOR and PI3K signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990449     DOI: 10.1016/j.molimm.2008.09.011

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin.

Authors:  Adam Whaley-Connell; Javad Habibi; Zachary Panfili; Melvin R Hayden; Sarika Bagree; Ravi Nistala; Safwan Hyder; Bennett Krueger; Vincent Demarco; Lakshmi Pulakat; Carlos M Ferrario; Alan Parrish; James R Sowers
Journal:  Am J Nephrol       Date:  2011-06-29       Impact factor: 3.754

2.  Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway.

Authors:  Adam T Whaley-Connell; Javad Habibi; Ravi Nistala; Vincent G DeMarco; Lakshmi Pulakat; Melvin R Hayden; Tejaswini Joginpally; Carlos M Ferrario; Alan R Parrish; James R Sowers
Journal:  Am J Nephrol       Date:  2011-12-24       Impact factor: 3.754

Review 3.  Advances in mammalian target of rapamycin kinase inhibitors: application to devices used in the treatment of coronary artery disease.

Authors:  Hiroyuki Jinnouchi; Liang Guo; Atsushi Sakamoto; Yu Sato; Anne Cornelissen; Rika Kawakami; Masayuki Mori; Sho Torii; Salome Kuntz; Emanuel Harari; Hiroyoshi Mori; Daniela Fuller; Neel Gadhoke; Raquel Fernandez; Ka Hyun Paek; Dipti Surve; Maria Romero; Frank D Kolodgie; Renu Virmani; Aloke V Finn
Journal:  Future Med Chem       Date:  2020-05-20       Impact factor: 3.808

4.  A Novel Insight into Endothelial and Cardiac Cells Phenotype in Systemic Sclerosis Using Patient-Derived Induced Pluripotent Stem Cell.

Authors:  Sedigheh Gholami; Zahra Mazidi; Sara Pahlavan; Fariba Moslem; Mahya Hosseini; Adeleh Taei; Mahdi Hesaraki; Maryam Barekat; Nasser Aghdami; Hossein Baharvand
Journal:  Cell J       Date:  2021-07-17       Impact factor: 2.479

5.  Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and -9: an in vitro study.

Authors:  Hua Gao; Jingjing Zhang; Ting Liu; Weiyun Shi
Journal:  Mol Vis       Date:  2011-12-24       Impact factor: 2.367

6.  MIR-99a and MIR-99b modulate TGF-β induced epithelial to mesenchymal plasticity in normal murine mammary gland cells.

Authors:  Gianluca Turcatel; Nicole Rubin; Ahmed El-Hashash; David Warburton
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

7.  Cardamonin Inhibits Metastasis of Lewis Lung Carcinoma Cells by Decreasing mTOR Activity.

Authors:  Pei-Guang Niu; Yu-Xuan Zhang; Dao-Hua Shi; Ying Liu; Yao-Yao Chen; Jie Deng
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

8.  Tuberin-deficiency downregulates N-cadherin and upregulates vimentin in kidney tumor of TSC patients.

Authors:  Sitai Liang; Tiffanie Salas; Emre Gencaslan; Baojie Li; Samy L Habib
Journal:  Oncotarget       Date:  2014-08-30

Review 9.  Neoatherosclerosis after Drug-Eluting Stent Implantation: Roles and Mechanisms.

Authors:  Yuanyuan Cui; Yue Liu; Fuhai Zhao; Dazhuo Shi; Keji Chen
Journal:  Oxid Med Cell Longev       Date:  2016-06-30       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.